

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
73
RLL-238US

In Re Application Of: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,049		Unassigned	26815	unknown	

Title: **DERIVATIVES OF 2,2,4-TRISUBSTITUTED TETRAHYDROFURAN AS ANTIFUNGAL AGENTS**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-238US

In Re Application: SALMAN et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,049		Unassigned	26815	unknown	

Title: DERIVATIVES OF 2,2,4-TRISUBSTITUTED TETRAHYDROFURAN AS ANTIFUNGAL AGENTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ^{EXPRESS} first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(e)] on ^{10/8} July 8, 2005

(Date)


Signature

Signature of Person Mailing Correspondence

Michelle Morgan

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Dated: July 8, 2005

George E. Heibel, Esq.
Reg. No. 42,648

CUSTOMER NO. 26815

CC:


INFORMATION DISCLOSURE CITATION

Docket No.: RLL-2-US

Serial No.: 10/511,049

Applicants: SALMAN et al.

Filed: 10/12/2004

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,992,421	2/12/1991	De et al.	514	19	
	A2	5,039,676	8/13/1991	Saksena et al.	514	254	
	A3	5,371,101	12/6/1994	Itoh et al.	514	383	
	A4	5,486,625	1/23/1996	Leong et al.	549	448	
	A5	5,661,151	8/26/1997	Saksena et al.	514	252	
	A6	5,703,236	12/30/1997	Saksena et al.	544	366	
	A7	6,034,248	3/7/2000	Itoh et al.	548	253	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	WO 98/34934	8/13/1998	PCT	C07D	405/14	
	B2	EP 0 252 875	1/27/1993	EPO	A01N	46/653	
	B3	EP 0 296 518	12/28/1988	EPO	C07D	405/14	
	B4	EP 0 335 446	10/4/1989	EPO	C07D	405/06	
	B5	EP 0 443 980	8/28/1991	EPO	C07D	417/06	
	B6	EP 0 539 938	5/5/1993	EPO	C07D	405/06	
	B7	EP 0 555 186	8/11/1993	EPO	B27K	3/34	
	B8	JP 9-12574	1/14/1997	Japan	C07D	405/06	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Fromtling, "Overview of Medically Important Antifungal Azole Derivatives", <i>Clinical Microbiology Reviews</i> , 1(2):187-217 (1988)
C2	Greenspan, "Treatment of oropharyngeal candidiasis in HIV-positive patients", <i>The Journal of the American Academy of Dermatology</i> , 31:S51-S55 (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-XXXXXXXXXX

Serial No.: 10/511,049

Applicants: SALMAN et al.

Filed: 10/12/2004

Group:

C3	Georgopapadakou and Walsh, "Antifungal Agents: Chemotherapeutic Targets and Immunologic Strategies", <i>Antimicrobial Agents and Chemotherapy</i> , <u>40</u> (2):279-291 (1996)
C4	Georgopapadakou, "Antifungals targeted to the cell wall", <i>Expert Opinion on Investigational Drugs</i> , <u>6</u> (2):147-150 (1997)
C5	Kauffman and Carver, "Antifungal Agents in the 1990s", <i>Drugs</i> , <u>53</u> (4):539-549 (1997)
C6	Koltin and Hitchcock, "The search for new triazole antifungal agents", <i>Current Opinion in Chemical Biology</i> , <u>1</u> :176-182 (1997)
C7	<u>Antifungal Agents</u> , "Principles and practice of infectious diseases", 4 th ed. pgs 401-410, G.L. Mandel, J.E. Bennett and R.Dolin (ed.), Churchill Livingstone, Inc. New York, N.Y
C8	Nguyen et al., "The Changing Face of Candidemia: Emergence of Non-Candida albicans Species and Antifungal Resistance", <i>The American Journal of Medicine</i> , <u>100</u> (6):617-623 (1996)
C9	Sheehan et al., "Current and Emerging Azole Antifungal Agents", <i>Clinical Microbiology Reviews</i> , <u>12</u> (1):40-79 (1999)
C10	Perfect et al., "In Vitro and In Vivo Efficacies of the Azole SCH56592 against <i>Cryptococcus neoformans</i> ", <i>Antimicrobial Agents and Chemotherapy</i> , <u>40</u> (8):1910-1913 (1996)
C11	36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1996, New Orleans. Abst. F74, F87-102
C12	Naito et al., "ER-34346 Triazole Antifungal", <i>Drugs of the Future</i> , <u>21</u> (1):20-24 (1996)
C13	Reimlinger et al., "Synthesen von s-Triazolo[3.4- α]isochinolinen", <i>Chem. Ber.</i> , <u>103</u> :1960-1981 (1970)
C14	Reimlinger et al., "Weitere Oxidationen kondensierter Isochinoline, Synthese o-Carboxyphenyl-substituierter Heterocyclen", <i>Chem. Ber.</i> , <u>108</u> :3799-3806 (1975)
C15	Kitazaki et al., "Optically Active Antifungal Azoles. VI. ¹⁾ Synthesis and Antifungal Activity of N-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N'-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones and 5(1H,4H)-tetrazolones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>44</u> (2):314-327 (1996)
C16	Saag et al., "Azole Antifungal Agents: Emphasis on New Triazoles", <i>Antimicrobial Agents and Chemotherapy</i> , <u>32</u> (1):1-8 (1988)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.